Plain-English translation of NCT05300282 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a type of immunotherapy medication that helps your immune system fight cancer, works better when combined with standard chemotherapy (called BEGEV) for people with Hodgkin's lymphoma that has returned or stopped responding to their first treatment. The study will also include a stem cell transplant and additional doses of the medication after the transplant to see if this combination approach helps more patients recover.
Hodgkin's lymphoma that comes back or doesn't respond to initial treatment is difficult to cure, and current standard options don't work for all patients. Researchers believe adding this medication to existing treatments might help patients achieve better results.
You likely qualify if…
You likely don't qualify if…
You will receive induction treatment with chemotherapy and the new medication given every 3 weeks for 4 cycles, with careful monitoring for side effects. If you respond well, you'll then receive stem cell mobilization, followed by a stem cell transplant. After the transplant, you'll receive additional doses of the medication alone every 4 weeks for 6 doses as consolidation therapy. You may also receive targeted radiation therapy during this phase. Throughout the trial, you'll have regular clinic visits, blood tests, and scans to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy